Literature DB >> 16505550

ESBL - from petri dish to the patient.

S Bhattacharya1.   

Abstract

Treatment of extended spectrum beta-lactamase (ESBL) producing strains of Enterobacteriaceae has emerged as a major challenge in hospitalised as well as community based patients. Infections due to ESBL producers range from uncomplicated urinary tract infection to life threatening sepsis. Although several reviews have been published in the literature about the detection and identification of these pathogens in the laboratory, there is not much guidance in Indian literature about how these organisms should be treated in clinical settings. The present article tries to address the clinical questions in the management of ESBL producing organisms. The article emphasises on antibiotic choice, pharmaco-therapeutic considerations, non-antibiotic aspects of management, and testing of clinical samples in the initial screening of patients for resistant gram negative organisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505550     DOI: 10.4103/0255-0857.19889

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  4 in total

1.  The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them.

Authors:  Bhaskar Thakuria; Kingshuk Lahon
Journal:  J Clin Diagn Res       Date:  2013-06-01

2.  Extended-spectrum β-lactamases in Gram Negative Bacteria.

Authors:  Deepti Rawat; Deepthi Nair
Journal:  J Glob Infect Dis       Date:  2010-09

3.  Prevalence and Genotypic Characterization of Extended-Spectrum Beta-Lactamases Produced by Gram Negative Bacilli at a Tertiary Care Hospital in Rural South Western Uganda.

Authors:  Acaku Moses; Freddie Bwanga; Yap Boum; Joel Bazira
Journal:  Br Microbiol Res J       Date:  2014-12

4.  Whole genome sequencing of extended-spectrum β-lactamase genes in Enterobacteriaceae isolates from Nigeria.

Authors:  Christiana Jesumirhewe; Burkhard Springer; Franz Allerberger; Werner Ruppitsch
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.